Linda T. H. Godding
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Linda T. H. Godding has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Juul M. P. A. van Den Reek
Department of Dermatology Radboud University Medical Centre Nijmegen the Netherlands
4 shared publications - Elke M. G. J. de Jong
Department of Dermatology Radboud University Medical Centre Nijmegen the Netherlands
3 shared publications - Sylvia van Beugen
Institute of Psychology, Health, Medical and Neuropsychology Unit Leiden University Leiden The Netherlands
2 shared publications A. Dekker-Klaassen
1 shared publicationAnnemarie Sluijmers
Nationale vereniging voor mensen met lupus, APS, sclerodermie en MCTD (NVLE) Utrecht the Netherlands
1 shared publication- Antoinette I. M. van Laarhoven
Health, Medical and Neuropsychology Unit, Leiden University, Leiden, the Netherlands
1 shared publication
Latest Publications
- Open Access
- 7 November 2026
- Published by Elsevier in JAAD International
Experiences and burden of people living with generalized pustular psoriasis: a qualitative study
- 7 November 2026
- Published by Elsevier in JAAD International
Open AccessExperiences and burden of people living with generalized pustular psoriasis: a qualitative study
- Open Access
- 3 October 2026
- Published by Elsevier in JID Innovations
- Vol. 7 (1)
A survival guide for drug survival studies in dermatology: Methodological approaches and best practices
- 3 October 2026
- Published by Elsevier in JID Innovations
- Vol. 7 (1)
Open AccessA survival guide for drug survival studies in dermatology: Methodological approaches and best practices
- Open Access
- 9 September 2026
- Published by Wiley in Experimental Dermatology
- Vol. 35 (9)
Future Integration of Biomarkers for Inflammatory Skin Diseases Into Daily Practice: A Survey Among a Multifaceted Group of Patients and Dermatological Care Providers
Successful implementation of dermatological biomarkers depends on early understanding of clinical needs and adoption barriers. Yet, research on these factors as perceived by dermatological care providers (DCPs) is scarce and perspectives of patients are largely underexplored. This survey study among patients and DCPs assessed biomarker needs and adoption barriers and facilitators for five inflammatory skin diseases: psoriasis (PsO), atopic dermatitis (AD), hidradenitis suppurativa (HS), cutaneous lupus erythematosus (CLE) and chronic spontaneous urticaria (CSU). In total, the study population consisted of 591 patients and 99 DCPs. Across all skin diseases, both groups mainly prioritized a biomarker for prediction of therapeutic response, however, DCPs prioritized this substantially more often than patients, especially for PsO (79.8% vs. 31.3% resp.), AD (68.7% vs. 37.1% resp.) and HS (66.7% vs. 34.4% resp.). Notably, a biomarker for the prediction of the risk to develop comorbidities was prioritized relatively often by patients (7.0%–19.4%), whereas DCPs only substantially prioritized this for CLE (14.1%). To enhance implementation, patients must ideally be able to undergo biomarker collection nearby their homes (travel time < 1 h) with complete reimbursement. For DCPs it is important that the biomarker is well validated, non‐invasive and measurable during regular visits with preferably a short sampling time.
- 9 September 2026
- Published by Wiley in Experimental Dermatology
- Vol. 35 (9)
Open AccessFuture Integration of Biomarkers for Inflammatory Skin Diseases Into Daily Practice: A Survey Among a Multifaceted Group of Patients and Dermatological Care Providers
Successful implementation of dermatological biomarkers depends on early understanding of clinical needs and adoption barriers. Yet, research on these factors as perceived by dermatological care providers (DCPs) is scarce and perspectives of patients are largely underexplored. This survey study among patients and DCPs assessed biomarker needs and adoption barriers and facilitators for five inflammatory skin diseases: psoriasis (PsO), atopic dermatitis (AD), hidradenitis suppurativa (HS), cutaneous lupus erythematosus (CLE) and chronic spontaneous urticaria (CSU). In total, the study population consisted of 591 patients and 99 DCPs. Across all skin diseases, both groups mainly prioritized a biomarker for prediction of therapeutic response, however, DCPs prioritized this substantially more often than patients, especially for PsO (79.8% vs. 31.3% resp.), AD (68.7% vs. 37.1% resp.) and HS (66.7% vs. 34.4% resp.). Notably, a biomarker for the prediction of the risk to develop comorbidities was prioritized relatively often by patients (7.0%–19.4%), whereas DCPs only substantially prioritized this for CLE (14.1%). To enhance implementation, patients must ideally be able to undergo biomarker collection nearby their homes (travel time < 1 h) with complete reimbursement. For DCPs it is important that the biomarker is well validated, non‐invasive and measurable during regular visits with preferably a short sampling time.
- Open Access
- 19 June 2024
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 35 (1) , 2369616
Psoriasis healthcare during the COVID-19 pandemic: a survey among psoriasis patients (PsoCovidCare)
During the COVID-19 pandemic, psoriasis care underwent significant changes in consultation methods and treatment management. However, comprehensive data on these changes and patient perceptions are limited. To evaluate the pandemic's implications on psoriasis patients, focusing on access to information, consultation methods, patient satisfaction, disease control assessment, and treatment management changes. A multicenter cross-sectional survey was performed in psoriasis patients from 4 dutch hospitals during the second wave of the pandemic. Among 551 respondents, approximately 55% received information their treatment in relation to COVID-19 from their treating physician, while 16.3% sought information online. Consultation methods were shifted to remote formats for 43.6% of patients, primarily via phone and the shift was often initiated by physicians. Overall patient satisfaction during the pandemic scored high (8.0), with remote consultations scoring between 8.0-9.0. Patients on biological treatment reported better disease control (8.0), compared to those on topical (6.0) or conventional systemic treatments (7.0). However, within the systemic treatment group and biologics group, a notable percentage interrupted (16.3% resp. 12.9%) or discontinued treatment (14.1 resp. 10.6%) during the pandemic. Disease control was moderate-to-good assessed by 75% of patients receiving face-to-face and 68% receiving remote consultations. Remote care appears to be a viable alternative to face-to-face consultations, with potential benefits in enhancing access to information provided by treating physicians.
- 19 June 2024
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 35 (1) , 2369616
Open AccessPsoriasis healthcare during the COVID-19 pandemic: a survey among psoriasis patients (PsoCovidCare)
During the COVID-19 pandemic, psoriasis care underwent significant changes in consultation methods and treatment management. However, comprehensive data on these changes and patient perceptions are limited. To evaluate the pandemic's implications on psoriasis patients, focusing on access to information, consultation methods, patient satisfaction, disease control assessment, and treatment management changes. A multicenter cross-sectional survey was performed in psoriasis patients from 4 dutch hospitals during the second wave of the pandemic. Among 551 respondents, approximately 55% received information their treatment in relation to COVID-19 from their treating physician, while 16.3% sought information online. Consultation methods were shifted to remote formats for 43.6% of patients, primarily via phone and the shift was often initiated by physicians. Overall patient satisfaction during the pandemic scored high (8.0), with remote consultations scoring between 8.0-9.0. Patients on biological treatment reported better disease control (8.0), compared to those on topical (6.0) or conventional systemic treatments (7.0). However, within the systemic treatment group and biologics group, a notable percentage interrupted (16.3% resp. 12.9%) or discontinued treatment (14.1 resp. 10.6%) during the pandemic. Disease control was moderate-to-good assessed by 75% of patients receiving face-to-face and 68% receiving remote consultations. Remote care appears to be a viable alternative to face-to-face consultations, with potential benefits in enhancing access to information provided by treating physicians.